116 related articles for article (PubMed ID: 7489747)
41. Development of a CD28 receptor binding-based screen and identification of a biologically active inhibitor.
Jenh CH; Zhang M; Wiekowski M; Tan JC; Fan XD; Hegde V; Patel M; Bryant R; Narula SK; Zavodny PJ; Chou CC
Anal Biochem; 1998 Feb; 256(1):47-55. PubMed ID: 9466796
[TBL] [Abstract][Full Text] [Related]
42. Characterization of CTLA-4 structure and expression on human T cells.
Lindsten T; Lee KP; Harris ES; Petryniak B; Craighead N; Reynolds PJ; Lombard DB; Freeman GJ; Nadler LM; Gray GS
J Immunol; 1993 Oct; 151(7):3489-99. PubMed ID: 8397258
[TBL] [Abstract][Full Text] [Related]
43. B7.1 expression eliminates tumor resistance to IL-12 gene therapy.
Heise CP; Shi F; Albertini MR; Mahvi DM
Cancer Gene Ther; 2001 Feb; 8(2):118-27. PubMed ID: 11263527
[TBL] [Abstract][Full Text] [Related]
44. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses.
Stamper CC; Zhang Y; Tobin JF; Erbe DV; Ikemizu S; Davis SJ; Stahl ML; Seehra J; Somers WS; Mosyak L
Nature; 2001 Mar; 410(6828):608-11. PubMed ID: 11279502
[TBL] [Abstract][Full Text] [Related]
45. Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion.
Ueda Y; Levine BL; Huang ML; Freeman GJ; Nadler LM; June CH; Ward SG
Int Immunol; 1995 Jun; 7(6):957-66. PubMed ID: 7577804
[TBL] [Abstract][Full Text] [Related]
46. Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population.
Anderson DE; Bieganowska KD; Bar-Or A; Oliveira EM; Carreno B; Collins M; Hafler DA
Nat Med; 2000 Feb; 6(2):211-4. PubMed ID: 10655112
[TBL] [Abstract][Full Text] [Related]
47. Anti-B7-1 blocks mononuclear cell adherence in vasa recta after ischemia.
De Greef KE; Ysebaert DK; Dauwe S; Persy V; Vercauteren SR; Mey D; De Broe ME
Kidney Int; 2001 Oct; 60(4):1415-27. PubMed ID: 11576355
[TBL] [Abstract][Full Text] [Related]
48. B7-1, IFN gamma and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma.
Van Ginderachter JA; Liu Y; Geldhof AB; Brijs L; Thielemans K; De Baetselier P; Raes G
Int J Cancer; 2000 Aug; 87(4):539-47. PubMed ID: 10918195
[TBL] [Abstract][Full Text] [Related]
49. Human naive and memory T-helper cells display distinct adhesion properties to ICAM-1, LFA-3 and B7 molecules.
Parra E; Wingren AG; Hedlund G; Sjögren HO; Kalland T; Sansom D; Dohlsten M
Scand J Immunol; 1993 Dec; 38(6):508-14. PubMed ID: 7504826
[TBL] [Abstract][Full Text] [Related]
50. Intrinsic and extrinsic manipulation of B7/CTLA-4 interaction for induction of anti-tumor immunity against osteosarcoma cells.
Nagamori M; Kawaguchi S; Murakami M; Wada T; Nagoya S; Yamashita T; Inobe M; Uede T
Anticancer Res; 2002; 22(6A):3223-7. PubMed ID: 12530068
[TBL] [Abstract][Full Text] [Related]
51. Suppression of experimental glomerulonephritis by interference with T- or B-cell activation signals or adhesion molecules.
Andres G; Nishikawa K; Stamenkovic I; McCluskey RT
Adv Nephrol Necker Hosp; 1995; 24():91-105. PubMed ID: 7572424
[No Abstract] [Full Text] [Related]
52. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1.
Linsley PS; Clark EA; Ledbetter JA
Proc Natl Acad Sci U S A; 1990 Jul; 87(13):5031-5. PubMed ID: 2164219
[TBL] [Abstract][Full Text] [Related]
53. Discordant expression of CD28 ligands, BB-1, and B7 on keratinocytes in vitro and psoriatic cells in vivo.
Nickoloff BJ; Mitra RS; Lee K; Turka LA; Green J; Thompson C; Shimizu Y
Am J Pathol; 1993 Apr; 142(4):1029-40. PubMed ID: 7682758
[TBL] [Abstract][Full Text] [Related]
54. Regulation of HIV production by blood mononuclear cells from HIV-infected donors: II. HIV-1 production depends on T cell-monocyte interaction.
Diegel ML; Moran PA; Gilliland LK; Damle NK; Hayden MS; Zarling JM; Ledbetter JA
AIDS Res Hum Retroviruses; 1993 May; 9(5):465-73. PubMed ID: 8100439
[TBL] [Abstract][Full Text] [Related]
55. In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity.
Denfeld RW; Dietrich A; Wuttig C; Tanczos E; Weiss JM; Vanscheidt W; Schöpf E; Simon JC
Int J Cancer; 1995 Jul; 62(3):259-65. PubMed ID: 7543078
[TBL] [Abstract][Full Text] [Related]
56. [Function of B7/CD28 in anti-myeloma immunoreaction through activating T cells].
Guo L; Zhang X; Qiu Y
Zhonghua Xue Ye Xue Za Zhi; 1999 May; 20(5):235-8. PubMed ID: 11601210
[TBL] [Abstract][Full Text] [Related]
57. Turning on tumor-fighting T-cells. Two signals are better than one when it come to developing new cancer therapies.
Edgington SM
Biotechnology (N Y); 1993 Oct; 11(10):1117-9. PubMed ID: 7691094
[No Abstract] [Full Text] [Related]
58. Immunology. Restless T cells sniff and go.
Mustelin T
Science; 2006 Sep; 313(5795):1902-3. PubMed ID: 17008518
[No Abstract] [Full Text] [Related]
59. Stimulation of human T lymphocytes by lipopolysaccaride (LPS) in the presence of autologous and heterologous monocytes.
Mattern T; Flad HD; Ulmer AJ
Prog Clin Biol Res; 1998; 397():243-54. PubMed ID: 9575565
[No Abstract] [Full Text] [Related]
60. Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human NK cells.
Lang S; Vujanovic NL; Wollenberg B; Whiteside TL
Eur J Immunol; 1998 Mar; 28(3):780-6. PubMed ID: 9541571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
